1. Media & Marketing

Key Predictions in the Accumulator/Maximizer Battle

Written by Posted on Less than 0 min read

Today’s guest post comes from Chris Dowd, Senior Vice President of Market Development at ConnectiveRx.

Chris discusses how such copay adjustment programs as accumulators and maximizers impact patients. He also discusses current legal cases that cover prescription medication access.

To learn more, register for ConnectiveRx’s free October online panel discussion with Chris: The Battle Over Accumulators and Maximizers: What You Need to Know for 2024.

Read on for Chris’ insights.

Read more »

Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Trends & External Forces

The Inflation Reduction Act: 10 Predictions About Market Access and Drug Channels (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding. Click here to see the original post from April 2023. Like it or not, the Centers for Medicare & Medicaid Services (CMS) is barreling ahead with […]
2 min read
0
  1. Shopper & Customer

How GoodRx is Evolving Its Reimbursement Approaches to Help Pharmacies and Consumers

Today’s guest post comes from Jim Sheninger, Pharmacy Strategy Officer at GoodRx. Jim describes GoodRx’s emerging pharmacy contracting strategies. In addition to working through pharmacy benefit managers (PBMs), GoodRx now also contracts directly with Walgreens, CVS, and other national and regional pharmacies. These direct agreements are based on acqusition cost, which helps pharmacies stabilize gross […]
2 min read
0
  1. Media & Marketing

How Discount Cards Work: A Primer on GoodRx and Its Competitors (video)

In my most recent video webinar, I explored how the rapid expansion of patient-paid prescriptions—via cash-pay pharmacies and discount card vendors—is transforming the prescription market. Below, I follow the dollar when a patient uses a discount card to pay for a generic drug prescription. As you’ll see, a discount card can save money for consumers […]
2 min read
0
  1. Trends & External Forces

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

I am pleased to announce the inaugural Drug Channels Leadership Forum! This unique, new event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. The Leadership Forum will be an executive gathering where drug channel leaders can network and discuss key issues and challenges facing the commercial […]
3 min read
0
  1. Partnerships & Alt Profit

New Survey Reveals Manufacturers’ Patient Services Priorities for 2024

Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Nasir shares findings from CareMetx’s new 2024 Patient Services Report research study: Revealing Manufacturer Priorities: Patients Naturally Take Center Stage. As he explains, manufacturers want hub partners that can take a holistic approach and address each patient’s individual needs. Nasir also discusses how […]
2 min read
0
  1. Data & Insights

The Promise and Challenges of Workflow Integration for Biopharma-Sponsored Patient Support Programs

Today’s guest post comes from Era Prakash, Vice President of Product Management at Cencora. Era contends that workflow integration can help biopharma companies address challenges that limit provider utilization of patient support programs. She also outlines three major challenges related to the provider workflow technology market. Click here to learn more about Cencora’s Access Network […]
2 min read
0
  1. Data & Insights

Harnessing Data to Improve Patient Access and Optimize Gross-to-Net

Today’s blog post comes from Andrew Duncan, Vice President of Business Operations and Analytics at PHIL. Andrew discusses how manufacturers can use data-driven strategy to understand utilization, increase patient access and adherence, and optimize gross-to-net. Click here to learn more about PHIL’s access and commercialization solutions. Read on for Andrew’s insights. Read more » Copyright […]
2 min read
0
  1. Shopper & Customer

The Evolution of Medical Benefit Contracting: How Pharma Can Prepare

Today’s guest post comes from Saket Patel, Consultant, Advisory Services at MMIT. Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. He then describes how to automate formulary and medical policies to protect manufacturers from overpayment. Click here to learn about MMIT’s Contract Validation solution. Read on […]
2 min read
0
  1. Technology & Innovation

What Pharmaceutical Manufacturers Value Most from a Hub

Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Nasir discusses how hubs help patients initiate and adhere to drug therapies. Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners. Learn more by downloading CareMetx’s full report: The Evolving Landscape of Digital Healthcare Hubs. […]
2 min read
0
  1. Trends & External Forces

Bracing for Impact: The Future of Hub, PAP, and Affordability Programs Under the Inflation Reduction Act

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris explains how the Inflation Reduction Act of 2022 (IRA) will impact hub, patient assistance programs (PAP), and affordability programs. He discusses steps manufacturers can take to accommodate the anticipated budget reductions while maintaining access and affordability for patients. To learn […]
2 min read
0
  1. Trends & External Forces

Medicare Part D in 2024: Mapping Large Chains’ Position in 2024’s Preferred Pharmacy Networks

In Medicare Part D in 2024: The Seven Largest Companies’ Preferred Pharmacy Networks and the Coming Collapse of the PDP Market, I documented how those networks now dominate stand-alone Medicare Part D prescription drug plans (PDPs) and have become a major presence in Medicare Advantage prescription drug (MA-PD) plans. Today, I examine the seven largest […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, December 2022: Vertical Integration Updated, Walgreens vs. Pharmacy, Cash-Pay Rx, Curing 340B, and Deductible Season

Whew. It was quite a year—one filled with big deals, big news, and big legislation. Drug Channels also had a big 2022. We now have 35,000 LinkedIn followers, almost 25,000 email subscribers, and nearly 16,000 Twitter followers. Thank you, dear readers, for welcoming me into your inboxes and browsers each week. I’ve had a blast […]
2 min read
0
  1. Data & Insights

Visit Drug Channels in Booth #1801 at #Asembia24 for a Special “Ask Me Anything With Adam” (#AMAWA)

Next week, the Drug Channels Institute team will be attending Asembia’s AXS24 Summit at the wonderful Wynn Las Vegas. And for the first time—thanks to our new friends at HMP Global—DCI will have its very own booth! (Click here for a special sneak peek.) As you might expect, we will hit Vegas in true Drug […]
3 min read
0
  1. Media & Marketing

Texas Shows Us Where PBMs’ Rebates Go (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Click here to see the original post and comments from August 2022. Over the weekend, the U.S. Senate passed a massive overhaul of the Medicare Part D program. If passed into law, these changes will […]
2 min read
0
  1. Media & Marketing

Four Crucial Questions about the Humira Biosimilar Price War

The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. market. As I predicted in 2021, some products launched with list prices that are only slightly lower than Humira’s list price, while others are trying to tempt payers and pharmacy benefit manages (PBMs) with deep list price discounts. […]
2 min read
0
  1. Media & Marketing

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha

As you’ve surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Our crazy drug channel led Amgen to launch both a high-list/high-rebate and a low-list/low-rebate version of the drug. Its strategy echoes the pricing of the first interchangeable insulin biosimilars—as I predicted in 2021. Unfortunately, we should expect most PBMs and […]
2 min read
0
  1. Data & Insights

More Than a Feeling: Five Key Challenges When Walking Away From Commercial/340B Duplicate Payments

Today’s guest post comes from Micah Litow, Chief Operating Officer at Kalderos. According to Kalderos, at least 5% of commercial rebates are paid for prescriptions that also have discounts under the 340B Drug Pricing Program. Micah outlines why it’s more than a feeling that manufacturers struggle to walk away from these duplicate payments. But as […]
2 min read
0
  1. Media & Marketing

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on our new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Since I published the article below in July 2023, there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of […]
3 min read
0
  1. Agencies & Vendors

Four Ways Digital Intake Can Transform Patient Support Programs, Overcome Access Barriers, and Improve Outcomes

Today’s guest post comes from Michael Carr, Group Vice President, CoAssist Pharmacy at AssistRx. Michael discusses the challenges that patients and healthcare providers face during the prescription intake and enrollment process. He outlines four key features of solutions that improve digital intake. To learn about AssistRx’s digital intake technologies, download their case study: Digital Intake […]
2 min read
0
  1. Media & Marketing

A Reality Check on That Blue Shield of California Announcement

Last week, Anna Matthews of The Wall Street Journal scored a market-moving scoop with her story about Blue Shield of California’s decision to ditch CVS Health’s Caremark pharmacy benefit manager (PBM) in favor of five separate vendors. ICYMI: A Big Health Insurer Is Ripping Up the Playbook on Drug Pricing I commend Blue Shield of […]
2 min read
0
Next